BDBM333121 (S)-(3-(dimethylamino)azetidin-1-yl)(2-(6-(2-ethyl-5-fluoro-4-hydroxyphenyl)-1H-indazol-3-yl)-5-propyl-4,5,6,7-tetrahydro-3H-imidazo[4,5-c]pyridin-6-yl)methanone::US10196393, Example 4::US10550118, Example 4::US10947229, Example C-5::US11453668, Example 4::US11634419, Example C-5

SMILES CCCN1Cc2[nH]c(nc2C[C@H]1C(=O)N1CC(C1)N(C)C)-c1n[nH]c2cc(ccc12)-c1cc(F)c(O)cc1CC

InChI Key InChIKey=RNWGSYOIILQORV-UHFFFAOYSA-N

Data  16 KI

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 16 hits for monomerid = 333121   

TargetTyrosine-protein kinase JAK2(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM333121(US10196393, Example 4 | (S)-(3-(dimethylamino)azet...)
Affinity DataKi:  0.0160nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/26/2021
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM333121(US10196393, Example 4 | (S)-(3-(dimethylamino)azet...)
Affinity DataKi:  0.0160nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/2/2023
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM333121(US10196393, Example 4 | (S)-(3-(dimethylamino)azet...)
Affinity DataKi:  0.0600nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/16/2019
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM333121(US10196393, Example 4 | (S)-(3-(dimethylamino)azet...)
Affinity DataKi:  0.0600nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2020
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM333121(US10196393, Example 4 | (S)-(3-(dimethylamino)azet...)
Affinity DataKi:  0.0600nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/28/2021
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM333121(US10196393, Example 4 | (S)-(3-(dimethylamino)azet...)
Affinity DataKi:  0.0600nMAssay Description:Assay 1: A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/4/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM333121(US10196393, Example 4 | (S)-(3-(dimethylamino)azet...)
Affinity DataKi:  0.0790nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/26/2021
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM333121(US10196393, Example 4 | (S)-(3-(dimethylamino)azet...)
Affinity DataKi:  0.0790nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/2/2023
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK3(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM333121(US10196393, Example 4 | (S)-(3-(dimethylamino)azet...)
Affinity DataKi:  0.100nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/26/2021
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK3(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM333121(US10196393, Example 4 | (S)-(3-(dimethylamino)azet...)
Affinity DataKi:  0.100nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/2/2023
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK3(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM333121(US10196393, Example 4 | (S)-(3-(dimethylamino)azet...)
Affinity DataKi:  0.130nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/16/2019
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK3(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM333121(US10196393, Example 4 | (S)-(3-(dimethylamino)azet...)
Affinity DataKi:  0.130nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2020
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK3(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM333121(US10196393, Example 4 | (S)-(3-(dimethylamino)azet...)
Affinity DataKi:  0.130nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/28/2021
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK3(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM333121(US10196393, Example 4 | (S)-(3-(dimethylamino)azet...)
Affinity DataKi:  0.130nMAssay Description:Assay 1: A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/4/2022
Entry Details
Go to US Patent

TargetNon-receptor tyrosine-protein kinase TYK2(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM333121(US10196393, Example 4 | (S)-(3-(dimethylamino)azet...)
Affinity DataKi:  0.398nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/26/2021
Entry Details
Go to US Patent

TargetNon-receptor tyrosine-protein kinase TYK2(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM333121(US10196393, Example 4 | (S)-(3-(dimethylamino)azet...)
Affinity DataKi:  0.398nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/2/2023
Entry Details
Go to US Patent